
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments is poised to continue its strong performance in the coming years, thanks to its innovative software platform, Clover Assistant, which has shown its ability to effectively manage chronic diseases and contain medical costs. With strong retention rates and growth focused on markets where CA has been widely adopted, the company is well positioned to profitably absorb new members and continue improving its unit economics. While there may be some headwinds in 2027 due to a potential downgrade to a 3.5-star plan and flat CMS advance rates, management remains confident that their focus on technology and improving care outcomes will drive profitability. Overall, Clover Health Investments' unique approach to healthcare and strong financial performance make it a promising investment opportunity.
Bears say
Clover Health Investments is a healthcare technology company with a proprietary software platform aimed at managing chronic diseases. While the company achieved profitability in 2025, future headwinds such as a potential decrease in star ratings and flat payment rates in 2027 present risks to future profitability. Additionally, the Clover Assistant platform is facing competition in the marketplace and any regulatory changes to Medicare Advantage could negatively impact the company's financial outlook.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares